Subsequent Events - Additional Information (Detail) - USD ($) |
3 Months Ended | |||
|---|---|---|---|---|
May 02, 2017 |
Apr. 20, 2017 |
Mar. 31, 2017 |
Mar. 22, 2017 |
|
| NASDAQ Stock Market LLC [Member] | ||||
| Subsequent Event [Line Items] | ||||
| Listing compliance description | the Company received a notice from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (the “Staff”) that the Company was not in compliance with the $50 million in total assets and total revenue standard for continued listing on the NASDAQ Global Market under NASDAQ’s Listing Rule 5450(b)(3)(A) and that the Company also did not comply with either of the two alternative standards of Listing Rule 5450(b), the equity standard and the market value standard. | |||
| Minimum stockholders equity and total revenue requirement for continued listing | $ 50,000,000 | |||
| Subsequent Event [Member] | NASDAQ Stock Market LLC [Member] | ||||
| Subsequent Event [Line Items] | ||||
| Minimum required market value of listed securities | $ 50,000,000 | |||
| Description of letter from listing qualifications staff | the Staff informed the Company that, following ten consecutive business days where the market value of the Company’s listed securities were $50 million or greater, the Company was in compliance with the NASDAQ Listing Rule 5450(b)(2)(A) and will continue to be listed on the NASDAQ Global Market. | |||
| Number of consecutive business days | 10 days | |||
| Novo Nordisk [Member] | ||||
| Subsequent Event [Line Items] | ||||
| Termination agreement, term description | The termination of the License Agreement will be effective 90 days from April 20, 2017 in accordance with Section 10.2 of the License Agreement. There was no financial impact resulting from the termination of the License Agreement with Novo Nordisk A/S. | |||
| Novo Nordisk [Member] | Subsequent Event [Member] | ||||
| Subsequent Event [Line Items] | ||||
| Termination agreement, notice period | 90 days |